Company intelligence / Profile preview

Micro Interventional Devices

Newtown, Pennsylvania, United Statesmicrointerventional.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Micro Interventional Devices has developed the MIA-T Percutaneous Tricuspid Annuloplasty System for treating tricuspid regurgitation. The system is being studied in the STTAR clinical trial and has received Breakthrough Device Designation from the FDA. The company focuses on minimally invasive solutions to replicate surgical procedures percutaneously and eliminate open-heart surgery for structural heart conditions.

Therapeutic areas: Cardiovascular
Modalities: DeviceCatheter-based technologyPercutaneous intervention device
Industry: Surgical Medical Devices

Drug pipeline

3 assets

Permaseal

Pre-clinical

Indications: Structural heart disease, Transcatheter aortic valve implantation

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Micro Interventional Devices.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Micro Interventional Devices.

Explore the full profile